Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omiganan topical gel in mild to moderate atopic dermatitis
2016-003849-28Phase 2Completed
- Sponsor
- Biofrontera
- Start
- Dec 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Omiganan BID with Placebo BID (2 arms). Primary endpoint: Pharmacodynamic endpoints. Started Dec 2016; status: completed.
02
Drugs
omiganan
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2016-003849-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003849-28.